Parameter
| Biomarker | PLA2G7 | Full name | Phospholipase A2 group VII | Molecular Type | Nucleic acid (mRNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, therapeutic targets | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues and cell lines (GEO/TCGA analysis, in vitro experiments) | ||
| Pathobiological Mechanisms | Participates in immune and proliferative processes, with the inhibitor daunorubicin capable of suppressing cellular viability. | ||||
| Clinical Availability Status | Research validation phase: Database screening and in vitro validation, followed by large-scale diagnostic efficacy evaluation and clinical trials. | ||||
| Notes and Dynamics | Advance preclinical studies of inhibitors to validate the diagnostic value of blood samples. | ||||